Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia.
Jehane FadlallahMarc MichelEtienne CrickxNicolas LimalNathalie CostedoatMarion MalphettesClaire FieschiLionel GalicierEric OksenhendlerBertrand GodeauSylvain AudiaMatthieu MahévasPublished in: British journal of haematology (2019)
We report the off-label use of bortezomib combined with dexamethasone in eight adults with severe and multi-refractory warm auto-immune haemolytic anaemia (wAIHA). After six cycles of induction therapy, 6 of the 8 patients achieved response (3 complete response, 3 response). Response was obtained after a median of 2 (1-4) cycles. After a median follow-up of 14 (6-36) months, six patients maintained a response (bortezomib/dexamethasone maintenance, n = 4); five patients experienced at least one moderate adverse event, including peripheral neuropathy (n = 2). These results suggest that bortezomib/dexamethasone combination is a promising approach with acceptable toxicity for treating severe refractory wAIHA in adults.